02.01.2015 Views

EMQs in Clinical Medicine.pdf - Peshawar Medical College

EMQs in Clinical Medicine.pdf - Peshawar Medical College

EMQs in Clinical Medicine.pdf - Peshawar Medical College

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

20 Cardiovascular medic<strong>in</strong>e<br />

D<br />

I<br />

F<br />

A<br />

A patient with AF of longer than 48 h duration is at risk of<br />

thromboembolism after cardioversion. Unless the patient is severely<br />

compromised, it is standard practice to anticoagulate the patient with<br />

warfar<strong>in</strong> for a month before attempt<strong>in</strong>g elective cardioversion. Dur<strong>in</strong>g<br />

that time the ventricular rate is controlled by prescrib<strong>in</strong>g digox<strong>in</strong>.<br />

Initial therapy <strong>in</strong> a 60-year-old woman present<strong>in</strong>g severely<br />

compromised with acute persistent AF.<br />

In this case immediate DC shock is <strong>in</strong>dicated because the patient is<br />

severely compromised. The adm<strong>in</strong>istration of hepar<strong>in</strong> decreases but does<br />

not abolish the risk of thromboembolism after cardioversion.<br />

A 55-year-old man admitted with an acute myocardial <strong>in</strong>farction<br />

develops a short run of VT. He requires treatment for prophylaxis<br />

aga<strong>in</strong>st recurrent VT.<br />

Amiodarone has class I, II, III and IV actions but is used cl<strong>in</strong>ically for its<br />

class III actions. Class III drugs prolong the plateau phase of the cardiac<br />

action potential and <strong>in</strong>crease the absolute refractory period. As a<br />

consequence they also prolong the Q–T <strong>in</strong>terval.<br />

Amiodarone is the drug of choice to treat VT. When it is used chronically<br />

it has a number of adverse effects but these are not an issue <strong>in</strong> the acute<br />

scenario. These adverse effects <strong>in</strong>clude bradycardia, pulmonary fibrosis,<br />

hepatic fibrosis, corneal microdeposits (regress if drug is stopped),<br />

photosensitive rash and thyroid dysfunction.<br />

Drug to aid diagnosis <strong>in</strong> a 50-year-old man present<strong>in</strong>g with an<br />

unidentifiable, regular, narrow-complex tachycardia.<br />

Adenos<strong>in</strong>e causes profound short-term AV block. In this way it can be<br />

used to term<strong>in</strong>ate tachycardias <strong>in</strong>volv<strong>in</strong>g an AV re-entry circuit. It may<br />

also be used <strong>in</strong> the diagnosis of an unidentified arrhythmia. Adenos<strong>in</strong>e<br />

can cause bronchoconstriction and stimulates nociceptive afferent<br />

neurons <strong>in</strong> the heart. The patient should be warned <strong>in</strong> advance that<br />

he may experience symptoms of chest pa<strong>in</strong> after the drug is<br />

adm<strong>in</strong>istered.<br />

E<br />

Prophylaxis of ventricular tachycardia <strong>in</strong> a patient with vary<strong>in</strong>g QRS<br />

axis and prolonged Q–T <strong>in</strong>terval.<br />

This is torsades de po<strong>in</strong>ts, which will often degenerate to ventricular<br />

fibrillation lead<strong>in</strong>g to cardiac arrest. Causes <strong>in</strong>clude drugs, electrolyte<br />

disturbance and congenital long Q–T syndrome. Conventional<br />

anti-arrhythmics will make this condition worse.<br />

The treatment of choice is <strong>in</strong>travenous magnesium sulphate and<br />

ventricular pac<strong>in</strong>g at a high rate.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!